Avidity Biosciences Inc (RNA)’s Ratio Roundup: Key Metrics for Trailing Twelve Months

In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

As of close of business last night, Avidity Biosciences Inc’s stock clocked out at $27.11, up 1.92% from its previous closing price of $26.60. In other words, the price has increased by $1.92 from its previous closing price. On the day, 1.09 million shares were traded. RNA stock price reached its highest trading level at $27.336 during the session, while it also had its lowest trading level at $25.85.


To gain a deeper understanding of RNA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 12.47 and its Current Ratio is at 12.47. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BofA Securities on May 03, 2024, initiated with a Buy rating and assigned the stock a target price of $40.

On March 14, 2024, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $60.

Evercore ISI Upgraded its In-line to Outperform on May 22, 2023, while the target price for the stock was maintained at $20.

Insider Transactions:

Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jun 04 ’24 when Boyce Sarah sold 28,000 shares for $27.42 per share. The transaction valued at 767,780 led to the insider holds 112,117 shares of the business.

LEVIN ARTHUR A sold 5,000 shares of RNA for $149,481 on May 20 ’24. The Director now owns 14,830 shares after completing the transaction at $29.90 per share. On May 14 ’24, another insider, MacLean Michael F, who serves as the Chief Financial Officer of the company, sold 75,000 shares for $28.28 each. As a result, the insider received 2,121,045 and left with 44,093 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RNA now has a Market Capitalization of 2592713728 and an Enterprise Value of 1685986176. For the stock, the TTM Price-to-Sale (P/S) ratio is 238.53 while its Price-to-Book (P/B) ratio in mrq is 3.12. Its current Enterprise Value per Revenue stands at 155.105 whereas that against EBITDA is -6.668.

Stock Price History:

Over the past 52 weeks, RNA has reached a high of $30.84, while it has fallen to a 52-week low of $4.82. The 50-Day Moving Average of the stock is 3.90%, while the 200-Day Moving Average is calculated to be 90.24%.

Shares Statistics:

It appears that RNA traded 1.06M shares on average per day over the past three months and 921980 shares per day over the past ten days. A total of 95.64M shares are outstanding, with a floating share count of 86.65M. Insiders hold about 9.40% of the company’s shares, while institutions hold 91.78% stake in the company. Shares short for RNA as of 1715731200 were 11308037 with a Short Ratio of 10.63, compared to 1713139200 on 10661773. Therefore, it implies a Short% of Shares Outstanding of 11308037 and a Short% of Float of 15.479999999999999.

Earnings Estimates

The dynamic stock of Avidity Biosciences Inc (RNA) is currently being evaluated by a team of 8.0 analysts, each contributing to its current rating.On average, analysts expect EPS of -$0.78 for the current quarter, with a high estimate of -$0.6 and a low estimate of -$0.94, while EPS last year was -$0.66. The consensus estimate for the next quarter is -$0.79, with high estimates of -$0.57 and low estimates of -$1.02.

Analysts are recommending an EPS of between -$2.48 and -$3.96 for the fiscal current year, implying an average EPS of -$3.17. EPS for the following year is -$3.35, with 9.0 analysts recommending between -$2.27 and -$4.39.

Most Popular